Author(s)

I.G. Kondrasheva, T.A. Antipova, G.G. Barsegyan, P.Ye. Gambaryan, A.A. Guseva, A.A. Kamensky

Moscow State University Moscow, Russia.
Research Center of Molecular Diagnostics & Therapy Moscow, Russia.

Inclusion of L-DOPA, the standard Parkinson’s disease medication, into polymeric particles (PLGA) results in optimization the drug metabolism and increasing its bioavailability, significantly increases of physical endurance, better coordination and lower anxiety in Wistar rats, when chronically administered nasally.

Nanopaticls; L-DOPA; Nasal Administration; Parkinson’s Disease

I. Kondrasheva, T. Antipova, G. Barsegyan, P. Gambaryan, A. Guseva and A. Kamensky, "Efficacy and Safety of Nasal Administration of “Na-no-L-DOPA” Based on PLGA Nanoparticles," Engineering, Vol. 4 No. 10B, 2012, pp. 27-29. doi: 10.4236/eng.2012.410B007.